|
1
|
Fox E, Levin K, Zhu Y, Segers B, Balamuth
N, Womer R, Bagatell R and Balis F: Pantoprazole, an inhibitor of
the organic cation transporter 2, does not ameliorate
cisplatin-related ototoxicity or nephrotoxicity in children and
adolescents with newly diagnosed osteosarcoma treated with
methotrexate, doxorubicin, and cisplatin. Oncologist. 23:e762–e779.
2018. View Article : Google Scholar
|
|
2
|
Endicott AA, Morimoto LM, Kline CN,
Wiemels JL, Metayer C and Walsh KM: Perinatal factors associated
with clinical presentation of osteosarcoma in children and
adolescents. Pediatr Blood Cancer. 64:e263492017. View Article : Google Scholar
|
|
3
|
Kebudi R, Ozger H, Kizilocak H, Bay SB and
Bilgic B: Osteosarcoma after hematopoietic stem cell
transplantation in children and adolescents: Case report and review
of the literature. Pediatr Blood Cancer. 63:1664–1666. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JA, Paik EK, Seo J, Kim DH, Lim JS,
Yoo JY and Kim MS: Radiotherapy and gemcitabine-docetaxel
chemotherapy in children and adolescents with unresectable
recurrent or refractory osteosarcoma. Jpn J Clin Oncol. 46:138–143.
2016.
|
|
5
|
Han Q, Li C, Cao Y, Bao J, Li K, Song R,
Chen X, Li J and Wu X: CBX2 is a functional target of miRNA let-7a
and acts as a tumor promoter in osteosarcoma. Cancer Med.
8:3981–3991. 2019.PubMed/NCBI
|
|
6
|
Huang C, Wang Q, Ma S, Sun Y, Vadamootoo
AS and Jin C: A four serum-miRNA panel serves as a potential
diagnostic biomarker of osteosarcoma. Int J Clin Oncol. 24:976–982.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang H, Zhao F, Cai S and Pu Y: MiR-193a
regulates chemoresistance of human osteosarcoma cells via
repression of IRS2. J Bone Oncol. 17:1002412019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu XG, Xu J, Li F, Li MJ and Hu T:
Down-regulation of miR-377 contributes to cisplatin resistance by
targeting XIAP in osteosarcoma. Eur Rev Med Pharmacol Sci.
22:1249–1257. 2018.PubMed/NCBI
|
|
9
|
Hu XH, Dai J, Shang HL, Zhao ZX and Hao
YD: MiR-1285-3p is a potential prognostic marker in human
osteosarcoma and functions as a tumor suppressor by targeting YAP1.
Cancer Biomark. 25:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chu Y, Hu X, Wang G, Wang Z and Wang Y:
Downregulation of miR-136 promotes the progression of osteosarcoma
and is associated with the prognosis of patients with osteosarcoma.
Oncol Lett. 17:5210–5218. 2019.PubMed/NCBI
|
|
11
|
Wang JY, Lu SB and Wang JQ: MiR-628-5p
promotes the growth and migration of osteosarcoma by targeting
IFI44L. Biochem Cell Biol. Apr 24–2019.(Epub ahead of print).
|
|
12
|
Ouyang L, Liu P, Yang S, Ye S, Xu W and
Liu X: A three-plasma miRNA signature serves as novel biomarkers
for osteosarcoma. Med Oncol. 30:3402013. View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crncec A and Hochegger H: Triggering
mitosis. FEBS Lett. 593:2868–2888. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schwentner R, Papamarkou T, Kauer MO,
Stathopoulos V, Yang F, Bilke S, Meltzer PS, Girolami M and Kovar
H: EWS-FLI1 employs an E2F switch to drive target gene expression.
Nucleic Acids Res. 43:2780–2789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Jiang M, Liu Q, Han Z, Zhao Y and
Ji S: MiR-145-5p inhibits the proliferation and migration of
bladder cancer cells by targeting TAGLN2. Oncol Lett. 16:6355–6360.
2018.PubMed/NCBI
|
|
18
|
Zhuang S, Liu F and Wu P: Upregulation of
long noncoding RNA TUG1 contributes to the development of
laryngocarcinoma by targeting miR-145-5p/ROCK1 axis. J Cell
Biochem. 120:13392–13402. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goeppert B, Truckenmueller F, Ori A, Fritz
V, Albrecht T, Fraas A, Scherer D, Silos RG, Sticht C, Gretz N, et
al: Profiling of gallbladder carcinoma reveals distinct miRNA
profiles and activation of STAT1 by the tumor suppressive
miRNA-145-5p. Sci Rep. 9:47962019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang B, Dong W and Li X: MiR-145-5p acts
as a novel tumor suppressor in hepatocellular carcinoma through
targeting RAB18. Technol Cancer Res Treat. 18:1533033819850189.
2019. View Article : Google Scholar
|
|
21
|
Tang W, Zhang X, Tan W, Gao J, Pan L, Ye
X, Chen L and Zheng W: MiR-145-5p suppresses breast cancer
progression by inhibiting SOX2. J Surg Res. 236:278–287. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng
Y, Xiao Z, Wang H and Zhu Y: Tumor suppressor miR-145-5p sensitizes
prolactinoma to bromocriptine by downregulating TPT1. J Endocrinol
Invest. 42:639–652. 2019. View Article : Google Scholar
|
|
23
|
Zhou T, Chen S and Mao X: MiR-145-5p
affects the differentiation of gastric cancer by targeting KLF5
directly. J Cell Physiol. 234:7634–7644. 2019. View Article : Google Scholar
|
|
24
|
Wu Z, Huang W, Wang X, Wang T, Chen Y,
Chen B, Liu R, Bai P and Xing J: Circular RNA CEP128 acts as a
sponge of miR-145-5p in promoting the bladder cancer progression
via regulating SOX11. Mol Med. 24:402018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen ZG, Liu XZ, Chen CX and Lu JM:
Knockdown of E2F3 inhibits proliferation, migration, and invasion
and increases apoptosis in glioma cells. Oncol Res. 25:1555–1566.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong D, Gong Y, Zhang D, Bao H and Gu G:
MiR-874 suppresses the proliferation and metastasis of osteosarcoma
by targeting E2F3. Tumour Biol. 37:6447–6455. 2016. View Article : Google Scholar
|
|
27
|
Jin Y, Wei J, Xu S, Guan F, Yin L and Zhu
H: MiR210-3p regulates cell growth and affects cisplatin
sensitivity in human ovarian cancer cells via targeting E2F3. Mol
Med Rep. 19:4946–4954. 2019.PubMed/NCBI
|
|
28
|
Liu J, Si L and Tian H: MicroRNA-148a
inhibits cell proliferation and cell cycle progression in lung
adenocarcinoma via directly targeting transcription factor E2F3.
Exp Ther Med. 16:5400–5409. 2018.PubMed/NCBI
|
|
29
|
Feng Z, Peng C, Li D, Zhang D, Li X, Cui
F, Chen Y and He Q: E2F3 promotes cancer growth and is
overexpressed through copy number variation in human melanoma. Onco
Targets Ther. 11:5303–5313. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han R, Chen X, Li Y, Zhang S, Li R and Lu
L: MicroRNA-34a suppresses aggressiveness of hepatocellular
carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Manag
Res. 11:2963–2976. 2019. View Article : Google Scholar :
|
|
31
|
Sun FB, Lin Y, Li SJ, Gao J, Han B and
Zhang CS: MiR-210 knockdown promotes the development of pancreatic
cancer via upregulating E2F3 expression. Eur Rev Med Pharmacol Sci.
22:8640–8648. 2018.PubMed/NCBI
|
|
32
|
Yang J, Zhang HF and Qin CF: MicroRNA-217
functions as a prognosis predictor and inhibits pancreatic cancer
cell proliferation and invasion via targeting E2F3. Eur Rev Med
Pharmacol Sci. 21:4050–4057. 2017.PubMed/NCBI
|
